Quantitative pathology and APOE genotype reveal dementia risk and progression in Lewy body disease
Quantitative Pathologie und APOE-Genotyp zeigen Demenzrisiko und -progression bei Lewy-Body-Erkrankung
Brain · 04.11.2026 · 149 (11) · 3905-3922
DOI: 10.1093/brain/awag114 ↗Auf einen Blick
Bei 399 postmortalen Gehirnen mit Lewy-Body-Erkrankung waren quantitative Pathologiemessungen besser für die Demenzvorhersage als konventionelles Staging. APOE-ɛ3- und ɛ4-Träger zeigten unterschiedliche Risikoprofile.
Fragestellung
Welchen Einfluss haben APOE-Genotyp, Ko-Pathologie und quantitative Pathologie auf Demenzrisiko und -progression bei Lewy-Body-Erkrankungen?
Methode
Analyse von 399 postmortalen Gehirnen von Patient:innen mit Parkinson-Krankheit, Parkinson-Demenz, Demenz mit Lewy-Körperchen und Kontrollen; Integration von APOE-Genotyp, Klinik und Ischämiepathologie sowie digitaler Pathologie.
Ergebnisse
Quantitative Pathologie korrelierte stark mit semiquantitativen Ratings und war der konventionellen Stadieneinteilung in der Demenzvorhersage überlegen. Orthostatische Hypotonie und ischämische Pathologie erhöhten das Demenzrisiko nur in ɛ3-Trägern mit niedriger Proteinopathielast.
Schlussfolgerung der Autor:innen
Die Kombination aus quantitativer Pathologie, Genotyp und klinischen Daten zeigt unterschiedliche, teils überlappende Wege zur Demenz bei LBD und kann die Modellierung des Krankheitsverlaufs verfeinern.
Kernaussagen
- Quantitative Pathologie sagte Demenz besser voraus als konventionelles Staging
- APOE ɛ3 und ɛ4 waren mit unterschiedlichen Demenzrisikoprofilen verbunden
- SuStaIn identifizierte vier Trajektorien der Lewy-Pathologie-Progression
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 27.03.2026. Verfasst von Hemanth R Nelvagal und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK. Hauptthemen laut MEDLINE: Lewy Body Disease, Brain, Apolipoproteins E, Dementia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aligning Science Across Parkinson's, Michael J. Fox Foundation for Parkinson's Research (MJFF), Aligning Science Across Parkinson’s.
Themen: Demenz
Abstract (Originalsprache)
Dementia in Lewy body diseases (LBD) is common and arises through heterogeneous and incompletely understood pathways. Evidence suggests contributions from genetic factors, including APOE ɛ4 genotype, and co-pathology, including concomitant Alzheimer’s disease pathology and hypoperfusion related to orthostatic hypotension. However, the relative impact of these factors remains unclear. To address this, we analysed 399 post-mortem brains from LBD cases comprising Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies, and controls, integrating APOE genotype, clinical data and assessment of ischaemic pathology alongside large-scale digital pathology quantification. We established an image analysis pipeline using machine learning to enable automated, standardized measurement of α-synuclein, amyloid-β and phosphorylated tau burden across multiple brain regions. Quantitative pathology was strongly correlated with semi-quantitative ratings and outperformed conventional staging in predicting dementia. Across multiple analytical approaches, APOE ɛ3 and ɛ4 carriers showed distinct dementia risk profiles. APOE ɛ3 carriers developed dementia at lower quantitative α-synuclein and amyloid-β thresholds than ɛ4 carriers, although overall dementia risk was dominated by ɛ4 genotype, consistent with ɛ4 both promoting greater pathology accumulation and modifying the threshold for dementia onset. Orthostatic hypotension and ischaemic pathology increased dementia risk only in ɛ3 carriers with low Lewy and Alzheimer’s proteinopathy burden, and male sex further modulated dementia risk for this subgroup. The Subtype and Stage Inference (SuStaIn) algorithm identified four trajectories of Lewy pathology progression. Two corresponded to recognized patterns: (i) brainstem first; and (ii) with early amygdala and concomitant brainstem involvement. Two further patterns showed early cortical involvement: (i) with early cingulate cortex involvement together with brainstem pathology; and (ii) starting in the neocortex before limbic and brainstem involvement. Co-pathology progression modelling identified subtypes with early predominance of amyloid-β, phosphorylated tau or α-synuclein and showed that Lewy subtypes follow two propagation trajectories in opposite directions. Together, these findings demonstrate that integrating quantitative pathology with genotype and clinical data reveals distinct yet overlapping pathways to dementia in LBD, refining disease progression models and providing a basis for genotype- and pathology-informed patient stratification in therapeutic trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
- Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London WC1N 1PJ, UK.
- Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK.
- Reta Lila Weston Institute of Neurological Studies, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
- Queen Square Movement Disorders Centre, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
ORCID-Profile: Hemanth R Nelvagal, Nancy Chiraki, Toby Curless, Patrick W Cullinane, Samarth Pimparkar, Haruka Kawamura, Isha Elahi, Sebastian Brandner, Lesley Wu, Raquel Real, Mina Ryten, John Hardy, Eduardo De Pablo Fernandez, Thomas T Warner, Huw R Morris, Yau Mun Lim, Zane Jaunmuktane
Förderung
- Aligning Science Across Parkinson's
- Michael J. Fox Foundation for Parkinson's Research (MJFF)
- Aligning Science Across Parkinson’s
- Michael J. Fox Foundation for Parkinson’s Research
Zitieren
APA
Nelvagal, H. R., Chiraki, N., Curless, T., Cullinane, P. W., Rockliffe, A., Pimparkar, S., Kawamura, H., Ollerenshaw, S., Elahi, I., Brandner, S., Wu, L., Real, R., Ryten, M., Hardy, J., De Pablo Fernandez, E., Warner, T. T., Morris, H. R., Lim, Y. M., & Jaunmuktane, Z. (2026). Quantitative pathology and APOE genotype reveal dementia risk and progression in Lewy body disease. Brain, 149(11), 3905-3922. https://doi.org/10.1093/brain/awag114
Vancouver
Nelvagal HR, Chiraki N, Curless T, Cullinane PW, Rockliffe A, Pimparkar S, et al. Quantitative pathology and APOE genotype reveal dementia risk and progression in Lewy body disease. Brain. 2026;149(11):3905-3922. doi:10.1093/brain/awag114
BibTeX
@article{Nelvagal2026,
author = {Nelvagal, Hemanth R and Chiraki, Nancy and Curless, Toby and Cullinane, Patrick W and Rockliffe, Alice and Pimparkar, Samarth and Kawamura, Haruka and Ollerenshaw, Sophie and Elahi, Isha and Brandner, Sebastian and Wu, Lesley and Real, Raquel and Ryten, Mina and Hardy, John and De Pablo Fernandez, Eduardo and Warner, Thomas T and Morris, Huw R and Lim, Yau Mun and Jaunmuktane, Zane},
title = {Quantitative pathology and APOE genotype reveal dementia risk and progression in Lewy body disease},
journal = {Brain},
year = {2026},
volume = {149},
number = {11},
pages = {3905--3922},
doi = {10.1093/brain/awag114}
}
EUVIMED